Skip to content

Price / sales at other companies

Amgen logo
AmgenAMGN
5.1×+0.2×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
24.8×-26.8×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
11.7×+5.0×
Biogen logo
BiogenBIIB
2.7×+0.7×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.6×-0.1×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.3×

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Calculated from Jazz Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's price / sales?
Jazz Pharmaceuticals (JAZZ) reported price / sales of 2.6× in Q1 2026.
How has Jazz Pharmaceuticals's price / sales changed year-over-year?
Jazz Pharmaceuticals's price / sales increased by 41.4% year-over-year, from 1.9× to 2.6×.
What is the long-term trend for Jazz Pharmaceuticals's price / sales?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's price / sales has grown at a -10.8% compound annual growth rate (CAGR), from 4.3× to 2.4×.
What does price / sales mean?
How many dollars investors pay for each dollar of the company's annual sales.
How do you interpret price / sales?
Useful when earnings are negative or volatile (e.g. early-stage or cyclical firms). Only comparable across companies with similar margins — a sales dollar is worth more at a high-margin business.
How does price / sales compare across companies?
Best compared within a margin cohort; a software P/S and a retailer P/S are not directly comparable.